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Summary 
Background Although acute respiratory infections can lead to cardiovascular complications, the effect of underlying 
cardiovascular risk on the incidence of acute respiratory infections and cardiovascular complications following acute 
respiratory infection in individuals without established cardiovascular disease is unknown. We aimed to investigate 
whether cardiovascular risk is associated with increased risk of acute respiratory infection and acute cardiovascular 
events after acute respiratory infection using 10 years of linked electronic health record (EHR) data in England.
Methods In this retrospective, population-based cohort study we used EHRs from primary care providers registered 
on the Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases in England. Eligible individuals were 
aged 40–64 years, did not have established cardiovascular disease or a chronic health condition that would make them 
eligible for influenza vaccination, were registered at a general practice contributing to the CPRD, and had linked 
Hospital Episode Statistics Admitted Patient Care data in England from Sept 1, 2008, to Aug 31, 2018. We classified 
cardiovascular risk on the basis of diagnosed hypertension and overall predicted cardiovascular risk, estimated by use 
of the QRISK2 risk-prediction tool (comparing a score of ≥10% [increased risk] with a score of <10% [low risk]). Using 
multivariable Poisson regression models, we calculated incidence rate ratios (IRRs) for systemic acute respiratory 
infection. Among individuals who had an acute respiratory infection, we used multivariable Cox regression to 
calculate hazard ratios (HRs) for the risk of acute cardiovascular events within 1 year of infection.
Findings We identified 6 075 321 individuals aged 40–64 years with data in the CPRD and linked data in the Hospital 
Episode Statistics Admitted Patient Care database between Sept 1, 2008, and Aug 31, 2018. Of these individuals, 
4 212 930 (including 526 480 [12·5%] with hypertension and 607 087 [14·4%] with a QRISK2 score of ≥10%) were 
included in the assessment of the incidence of acute respiratory infection. After adjusting for confounders (age, sex, 
ethnicity, socioeconomic status, body-mass index, alcohol consumption, smoking status, and consultation frequency 
in the hypertension analysis; and alcohol consumption and consultation frequency in the QRISK2 analysis), the 
incidence of acute respiratory infection was higher in individuals with hypertension than those without (IRR 1·04 
[95% CI 1·03–1·05]) and higher in those with a QRISK2 score of 10% or higher than in those with a QRISK2 score of 
less than 10% (1·39 [1·37–1·40]). Of the 442 408 individuals who had an acute respiratory infection, 4196 (0·9%) had 
an acute cardiovascular event within 1 year of infection. After adjustment (for age, sex, ethnicity, socioeconomic 
status, body-mass index, alcohol consumption, and smoking status in the hypertension analysis; and for alcohol 
consumption in the QRISK2 analysis), hypertension (HR 1·98 [95% CI 1·83–2·15]) and a QRISK2 score of 10% or 
higher (3·65 [3·42–3·89]) were associated with a substantially increased risk of acute cardiovascular events after acute 
respiratory infection.
Interpretation People with increased cardiovascular risk but without diagnosed cardiovascular disease, measured by 
diagnosed hypertension or overall predicted cardiovascular risk, could benefit from influenza and pneumococcal 
vaccine prioritisation to reduce their risk of both acute respiratory infection and cardiovascular complications 
following an acute respiratory infection. 
Funding British Heart Foundation and the Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
The COVID-19 pandemic has expedited research on 
cardiovascular complications following systemic acute 
respiratory infection. Before the pandemic, obser vational 
studies showed that acute respiratory infections increased 
the risk of myocardial infarction and stroke. In self-
controlled case-series using large electronic health record 
(EHR) datasets, risk of myocardial infarction and stroke 
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was elevated by 2–6 times in the days following clinically 
diagnosed acute respiratory infection, with the risk 
remaining elevated for up to 1 month.1,2 A range of 
organisms, including Streptococcus pneumoniae and the 
influenza virus, are known to trigger cardiovascular 
events.3,4
Observational studies and the few randomised 
controlled trials (RCTs) published to date show that 
pneumococcal and influenza vaccines reduce the risk 
of cardiovascular complications when compared with 
placebo or no vaccine.5–7 A meta-analysis of secondary 
prevention RCTs found that influenza vaccination 
reduced cardiovascular mortality by 55%.7 Pneumococcal 
vaccination reduced the odds of acute coronary syndrome 
by 17% in a meta-analysis of observational studies 
conducted among individuals aged 65 years or older.5
In Europe, people with underlying cardiovascular risk 
but without established cardiovascular disease are not 
typically recommended to receive seasonal influenza 
or pneumococcal vaccines.8–10 Public Health England 
Research in context
Evidence before this study
Before the COVID-19 pandemic, self-controlled case-series 
estimated a 2–6 times transient increase in the risk of 
myocardial infarction and stroke following a range of clinically 
diagnosed or laboratory-confirmed acute respiratory infections. 
These studies did not explore whether these effects were 
modified by underlying cardiovascular risk. We searched PubMed 
using the search terms “*hypertensi*” OR “cardiovascular risk” 
AND “influenza” OR “pneumonia” OR “respiratory infection” 
AND “cardiovascular event” OR “myocardial infarction” OR 
“acute coronary syndrome” OR “stroke” OR “heart failure” for 
primary research studies and reviews investigating the effect of 
underlying cardiovascular risk on cardiovascular complications 
after acute respiratory infection published in any language, from 
database inception to Jan 25, 2021. Of 421 studies identified, 
three presented estimates for the effect of cardiovascular risk on 
cardiovascular complications after acute respiratory infection. 
One prospective cohort study of individuals with community-
acquired pneumonia from five North American medical centres 
in 1991–94 showed that arterial hypertension was associated 
with an increased odds of cardiac complications (new or 
worsening heart failure, new or worsening arrhythmias, or 
myocardial infarction) within 30 days of a diagnosis of 
community-acquired pneumonia. The second study used clinical 
records from Beijing, China, to explore risk factors for 
cardiovascular complications after hospitalisation for 
community-acquired pneumonia in 2013–15, and found that 
patients hospitalised with community-acquired pneumonia 
who had cardiovascular complications had a significantly higher 
prevalence of hypertension than those without cardiovascular 
complications. The final study used UK primary care electronic 
health records (EHRs) to identify individuals who had a 
myocardial infarction or stroke in 1995–2004 and matched (on 
year of birth, sex, primary care practice, and calendar time) 
controls. The authors found that individuals who had an acute 
respiratory infection in the previous month had an increased 
odds of having a first myocardial infarction or stroke, regardless 
of background cardiovascular risk. The effect of underlying 
cardiovascular risk on cardiovascular complications after acute 
respiratory infection therefore remains unclear. We also did a 
search of PubMed on Sept 28, 2021, using the search terms 
“*hypertensi*” OR “cardiovascular risk” AND “influenza” OR 
“pneumonia” OR “respiratory infection”. We searched for 
research articles or reviews published in any language between 
database inception and Jan 1, 2021. Of the 2175 studies 
identified, one presented estimates for the effect that 
cardiovascular risk has on the incidence of acute respiratory 
infections itself. The study used UK Biobank data to show that 
hypertension was independently associated with an increased 
risk of acute lower respiratory infections, particularly 
pneumonia.
Added value of this study
Using primary and secondary care EHRs from more than 
4·2 million individuals in England, we found that the incidence 
of acute respiratory infection, particularly pneumonia, was 
higher in those with increased cardiovascular risk, defined as 
diagnosed hypertension or a QRISK2 10-year risk score of 10% or 
more. In addition, individuals with increased cardiovascular risk 
also had an elevated risk of acute cardiovascular events after an 
acute respiratory infection. This risk was more pronounced 
when QRISK2 score, which incorporates multiple factors 
associated with cardiovascular disease onset, was used rather 
than a diagnosis of hypertension alone. Therefore, QRISK2 
provides a practical method to identify individuals at risk of 
cardiovascular complications after acute respiratory infection 
and to thereby prevent early-onset cardiovascular disease.
Implications of all the available evidence
Our analyses and the available evidence to date indicate that 
individuals with increased cardiovascular risk have a higher risk 
of acute respiratory infection, and that these infections are more 
likely to trigger acute cardiovascular events than in those 
without increased cardiovascular risk. These findings highlight 
the importance of managing and reducing cardiovascular risk to 
reduce acute respiratory infections and their consequences. 
Individuals with increased cardiovascular risk have not been 
considered at high risk of SARS-CoV-2 infection or COVID-19 
complications in policy decisions; however, hypertension has 
been associated with an increased risk of severe outcomes in 
most analyses. Individuals with increased cardiovascular risk are 
not typically targeted for seasonal influenza or pneumococcal 
vaccines, and have not been prioritised in the roll-out of 
COVID-19 vaccines. The prevention or treatment of acute 
respiratory infection in individuals with increased cardiovascular 
risk, as well as in those with established cardiovascular disease, 
could reduce the risk of cardiovascular events.
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recommends a one-time polysaccharide pneumococcal 
vaccine and seasonal influenza vaccines for adults aged 
65 years or older and for those aged younger than 
65 years with specific underlying health conditions, 
including chronic heart disease.9,10 
An association between high blood pressure and 
cardiovascular complications has been observed in 
individuals as young as 40 years of age.11 Blood pressure 
is an essential predictor of cardiovascular risk, but it is 
only one component. Cardiovascular risk scores such as 
the QRISK212 are increasingly used to predict an 
individual’s likelihood, most commonly the 10-year risk, 
of future cardiovascular disease on the basis of multiple 
factors. The National Institute for Health and Care 
Excellence recommends the use of the QRISK2 score for 
assessment and management of cardiovascular disease.13
Little is known about the effect of cardiovascular risk 
on the risk of acute respiratory infection; however, 
a recent UK Biobank study showed that high blood 
pressure increased the risk of acute respiratory infection, 
particularly pneumonia and influenza.14 Similarly, the 
role of cardiovascular risk in the association between 
acute respiratory infection and cardiovascular compli-
cations has only been sporadically studied. We identified 
two previous studies that reported an association between 
hypertension and cardiovascular complications after 
pneumonia.15,16 Another previous study investigated the 
association between overall cardiovascular risk and 
myocardial infarction and stroke after acute respiratory 
infection.17 This previous study reported an increased 
risk of myocardial infarction and stroke after acute 
respiratory infection, regardless of cardiovascular risk 
level. Cardiovascular risk was derived from associations 
identified in univariable analysis (angina, hypertension, 
hyperlipidaemia, diabetes, chronic heart disease among 
first degree relatives, peripheral vascular disease, 
smoking status, and previous stroke for myocardial 
infarction, and hypertension, diabetes, peripheral 
vascular disease, smoking status, previous myocardial 
infarction, and urinary tract infection for stroke) rather 
than a pre-existing risk score.17
In this study, we aimed to investigate how cardiovascular 
risk, defined by diagnosed hypertension or QRISK2 score, 
is associated with the risk of acute respiratory infection 
and acute cardiovascular events after acute respiratory 
infection using 10 years of linked EHR data in England.
Methods 
Study design and data sources 
We did a retrospective cohort study using routinely 
collected primary care data from the Clinical Practice 
Research Datalink (CPRD). The CPRD collects 
anonymised coded data from general practices in 
England through the GOLD database using the Vision 
clinical management system and Aurum database 
using the EMIS clinical management system.18,19 The 
databases include more than 35 million individuals, 
representative of the UK population in terms of age, 
sex, and ethnicity. The coded data collected include 
diagnoses, prescriptions, immunisations, and basic 
demographic characteristics.
Consenting general practices have patient records 
linked to other data sources. We used linked secondary 
care data from the Hospital Episode Statistics Admitted 
Patient Care (HES APC) database, data on deaths from 
the Office for National Statistics (ONS), and individual-
level Townsend deprivation index scores. HES APC data 
contain information on diagnoses made and procedures 
done for all National Health Service (NHS) admissions 
in England, coded with the International Classification of 
Diseases version 10 (ICD-10).20 The ONS mortality data 
contain information on the date and cause of death, also 
coded with the ICD-10.
The CPRD Independent Scientific Advisory Committee 
approved this study (19_209). The CPRD provided data 
on relevant HES APC, ONS, and Townsend index 
variables for the study population. The London School of 
Hygiene & Tropical Medicine provided ethical approval 
(17894).
The study protocol and data analysis plan are available 
in the appendix (pp 21–31).
Participants 
Eligible individuals were aged 40–64 years, not already 
recommended for seasonal influenza vaccination 
according to current UK guidelines,9 and registered at a 
general practice contributing to the CPRD (via GOLD or 
Aurum) with linked HES APC data in England from 
Sept 1, 2008, to Aug 31, 2018. This time period covered 
the duration of QRISK2 use. We started follow-up in 
September as this is when primary care practices identify 
individuals eligible for the seasonal influenza vaccine. 
We selected individuals aged 40–64 years to include 
those who had an increased likelihood of having a high 
cardiovascular risk or acute cardiovascular events, or 
both, but who were younger than the age cutoff for 
universal influenza vaccination. We defined the start of 
follow-up as Sept 1, 2008, the individual’s 40th birthday, 
or the research standard CPRD date (12 months after 
current registration in the Aurum dataset, and the latest 
of 12 months after the current registration or the practice 
research standard in the GOLD dataset), whichever 
came first.
We excluded individuals who had established cardio-
vascular disease, received a previous pneumococcal 
vaccine, received an influenza vaccine within the 
previous 12 months, or a chronic health condition 
making them eligible for influenza vaccination, recorded 
in the CPRD at baseline. We defined conditions 
recommended for influenza vaccination as chronic liver 
disease, chronic respiratory disease, stage 3–5 chronic 
kidney disease, diabetes, asplenia or other splenic 
dysfunction, chronic neurological conditions, severe 
obesity (ie, a body-mass index [BMI] of ≥40 kg/m²), or an 
See Online for appendix
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immunosuppressive condition.9 Full exclusion criteria 
are provided in the appendix (p 2). 
Individual patient consent was not required to collect 
the original underlying data because data were generated 
during routine clinical encounters. Consent was given at 
the general practice level for anonymised primary care 
data to be used for research through contributing to the 
CPRD. Patients can advise their general practice if they 
wish to opt out of data collection. For our research we 
have obtained the data from the CPRD following their 
approval process. 
Outcomes and variables 
We used the whole study population to investigate 
the incidence of acute respiratory infection. We ended 
follow-up at diagnosis of cardiovascular disease or a 
chronic condition with which an individual would 
be recommended for influenza vaccination, receipt of 
pneumococcal or influenza vaccination, death, transfer 
out of general practice, the date of last data collection from 
general practice, the individual’s 65th birthday, or 
Aug 31, 2018, whichever came first (appendix p 3).
We defined acute respiratory infection as a clinical or 
confirmed diagnosis of pneumonia, acute bronchitis, 
influenza, influenza-like illness, or other acute infections 
suggestive of lower respiratory tract involvement in the 
CPRD or HES APC record. Selected diagnostic codes 
were based on the code lists used in a previous study.2 We 
did not include symptoms in our definition. In further 
analyses, we analysed the incidence of influenza or 
influenza-like illness and pneumonia separately. For 
each individual, we grouped acute respiratory infection 
records within 28 days into a single episode (see 
appendix [p 3] for full details).
Within the study population, individuals with an acute 
respiratory infection were followed up from diagnosis to 
investigate the incidence and risk of acute cardiovascular 
events after this infection. Follow-up for this study 
population ended at the occurrence of an acute 
cardiovascular event, death, transfer out of general 
practice, the date of last data collection from general 
practice, 1 year after diagnosis of the acute respiratory 
infection, or Aug 31, 2018, whichever came first (appendix 
p 3).
For our main analysis, we used a broad definition for 
acute cardiovascular events of acute coronary syndrome 
(myocardial infarction and unstable angina), left 
ventricular heart failure, stroke or transient ischaemic 
attack, acute limb ischaemia, or cardiovascular death. We 
included diagnoses recorded in the CPRD or HES APC, 
with the codes used informed by previous studies,21 and 
cardiovascular deaths (ICD-10 codes I00–I99) recorded 
by the ONS. In further analyses, we also assessed each 
cardiovascular condition separately.
We considered two measures of cardiovascular risk: 
diagnosed hypertension and QRISK2 score. QRISK2 is a 
prediction algorithm that estimates an individual’s 10-year 
risk of cardiovascular disease.12 The risk factors included 
and the process we used to calculate QRISK2 scores are 
outlined in the appendix (p 4). Briefly, a score is calculated 
using a range of risk factors, such as age, sex, ethnicity, 
socioeconomic status, comorbid health conditions, BMI, 
blood pressure reading, and smoking status. QRISK2 is 
not widely used outside the UK; therefore, we also 
included hypertension as a pragmatic definition of 
cardiovascular risk. To ensure that we included only 
individuals with persistent and diagnosed hypertension, 
we used coded CPRD diagnoses with no time limit.
Individuals were classified as having increased 
cardiovascular risk (ie, diagnosed hypertension or a 
QRISK2 score of ≥10%) or not (no hypertension or a 
QRISK2 score of <10%) at baseline, and their risk was 
updated if hypertension was recorded or new measures 
relevant to the QRISK2 algorithm resulted in a change in 
QRISK2 score from less than 10% to 10% or higher 
during follow-up.
We considered demographics, lifestyle factors, and 
primary care consultation frequency in analyses of 
hypertension and acute respiratory infection. The 
demographic features were age (5-year bands of 40–44, 
45–49, 50–54, 55–59, and 60–64 years), sex (male and 
female), race or ethnicity (White, Black, south Asian, 
and mixed or other), and socioeconomic status 
(individual-level Townsend score data grouped into 
quintiles, ranging from least deprived [quintile 1] to 
most deprived [quintile 5]). The lifestyle factors were 
baseline alcohol consumption (heavy drinking [defined 
as either a recorded intake of >42 units per week or a 
diagnostic code suggestive of alcohol addiction or 
excessive alcohol consumption] or no known heavy 
drinking), smoking status (current smoker, never 
smoker, or former smoker), and BMI (underweight 
[BMI <18·5 kg/m²], normal [BMI 18·5–24·9 kg/m²], 
overweight [BMI 25·0–29·9 kg/m²], or obese 
[BMI 30·0–39·9 kg/m²]). Consultation frequency was 
derived from the number of in-person or telephone 
consultations in the year before baseline. For analyses 
involving QRISK2 scores, we included only alcohol 
consumption and consultation frequency, as all other 
factors are included in the QRISK2 algorithm. We 
identified these included covariates using CPRD data, 
with data on race or ethnicity additionally collected from 
the HES APC database.
Our analyses of acute cardiovascular events after acute 
respiratory infection included the aforementioned 
demographic and lifestyle factors. We stratified results by 
statin, antihypertensive, or antiplatelet prescriptions 
recorded in the CPRD in the year before infection. Our 
rationale for covariate and effect-modifier selection is 
explained in the appendix (p 4). 
Statistical analysis 
We pooled individual-level data from the CPRD GOLD 
and Aurum databases. We calculated age-stratified 
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acute respiratory infection incidence rates by 
cardiovascular risk. We used multivariable Poisson 
regression to calculate incidence rate ratios (IRRs). To 
account for multiple episodes of acute respiratory 
infection per individual, the random-effects models 
included time-updated exposure by age and 
cardiovascular risk. We initially adjusted for age and 
sex before adjusting for additional covariates (age, sex, 
ethnicity, socioeconomic status, BMI, alcohol intake, 
smoking status, and consultation frequency in the 
hypertension analysis; and alcohol consumption and 
consultation frequency in the QRISK2 analysis). A 
complete case-analysis approach was used in 
multivariable analyses. We did not do multiple 
imputation because data in CPRD are unlikely to be 
missing at random. Among individuals with an acute 
cardiovascular event within 1 year of acute respiratory 
infection, we summarised (using medians [IQRs]) the 
time between  the infection and event. To assess the 
effect of cardiovascular risk on acute cardiovascular 
events after acute respiratory infection, we used 
multivariable Cox proportional hazards regression 
finely adjusted for time under follow-up. We used 
robust standard errors and initially adjusted for age and 
sex before adjusting for additional covariates (age, sex, 
ethnicity, socioeconomic status, BMI, alcohol consump-
tion, and smoking status in the hypertension analysis; 
and alcohol intake in the QRISK2 analysis). In all 
analyses, for individuals who entered and exited 
follow-up on the same day, we added 1 day to ensure all 
individuals contributed at least 1 day of follow-up. 
Additionally, we separately added an interaction term to 
our Cox random-effects models for statin, antihyper-
tensive, or antiplatelet prescriptions, and compared the 
results to models without interaction.
We did five prespecified sensitivity analyses. First, we 
validated results obtained from combined individual-level 
GOLD and Aurum data by analysing each database 
separately before combining them with a random-
effects meta-analysis. Between-database heterogeneity 
was assessed by use of the I² statistic. Second, we 
excluded only individuals eligible for both pneumococcal 
and influenza vaccines (see appendix p 2).9,10 Third, we 
repeated the analyses restricted to individuals with a 
QRISK2 score recorded by their general practitioner and 
collected in the CPRD from Jan 1, 2015, to Dec 31, 2017 
(see appendix p4 for further detail of why this restricted 
time period was used), to compare results with those of 
our calculated QRISK2 scores and ensure consistent 
Cohort (n=4 212 930)
Age, years
40–44 1 920 369 (45·6%)
45–49 782 897 (18·6%)
50–54 612 202 (14·5%)
55–59 490 619 (11·6%)
60–64 406 843 (9·7%)
Sex
Male 2 226 561/4 212 898 (52·9%)
Female 1 986 337/4 212 898 (47·1%)
Race or ethnicity
White 3 242 107/3 702 718 (87·6%)
South Asian 194 931/3 702 718 (5·3%)
Black 154 270/3 702 718 (4·2%)
Mixed or other 111 410/3 702 718 (3·0%)
Townsend quintile
1 (least deprived) 1 004 670/4 207 605 (23·9%)
2 905 691/4 207 605 (21·5%)
3 825 679/4 207 605 (19·6%)
4 739 187/4 207 605 (17·6%)
5 (most deprived) 732 378/4 207 605 (17·4%)
BMI category*†
Underweight 51 002/3 447 604 (1·5%)
Normal weight 1 449 683/3 447 604 (42·0%)
Overweight 1 274 701/3 447 604 (37·0%)
Obese 672 218/3 447 604 (19·5%)
Smoking status*
Non-smoker 1 686 919/4 082 791 (41·3%)
Current smoker 1 076 707/4 082 791 (26·4%)
Former smoker 1 319 165/4 082 791 (32·3%)
Alcohol consumption*
No known heavy drinking 3 477 336/3 674 494 (94·6%)
Heavy drinking‡ 197 158/3 674 494 (5·4%)
Data are n (%) or n/N (%). BMI=body-mass index. *Closest measure before the 
start of follow-up. †Underweight was defined as a BMI of <18·5 kg/m², normal 
weight as a BMI of 18·5–24·9 kg/m², overweight as a BMI of 25·0–29·9 kg/m², and 
obese as a BMI of 30·0–39·9 kg/m². ‡Defined as either a recorded intake of more 
than 42 units per week or a diagnostic code suggestive of alcohol addiction or 
excessive alcohol consumption.
Table 1: Baseline demographic and lifestyle characteristics
Figure 1: Study profile
CPRD=Clinical Practice Research Datalink. *Identified from linked Office for 
National Statistics mortality data.
6 075 321 individuals aged 40–64 years were included in the CPRD 
GOLD and Aurum databases and in follow-up between 
Sept 1, 2008, and Aug 31, 2018, with linked data
4 212 930 included in assessment of the incidence of acute respiratory 
infections
442 208 included in assessment of the risk of acute cardiovascular 
events after acute respiratory infections 
1 862 391 excluded
644 395 were removed from GOLD dataset because their 
practice was also included in the Aurum dataset 
186 022 had cardiovascular disease
819 826 had an existing vaccine-eligible condition
211 114 had received a previous influenza or 
pneumococcal vaccine 
1034 died before the start of study follow-up period* 
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results were obtained. Fourth, we included only major 
adverse cardiovascular events of myocardial infarction, 
heart failure, stroke, and cardiovascular death in the 
cardio vascular event outcome. Finally, we repeated the 
analysis of acute cardiovascular events after acute 
respiratory infection excluding individuals who received 
pneumo coccal or influenza vaccines during follow-up.
All statistical analyses were done using Stata, 
version 16.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
6 075 321 individuals aged 40–64 years included in the 
GOLD and Aurum databases were in follow-up and had 
linked data in the HES APC between Sept 1, 2008, and 
Aug 31, 2018, of whom 4 212 930 eligible individuals 
(773 362 from the GOLD and 3 439 568 from the Aurum 
database) were included in the final cohort (figure 1). 
Individuals were followed up for a median of 3·9 years 
(IQR 1·6–7·6), 2 226 561 (52·9%) of 4 212 898 with 
available data on sex were men, 1 986 337 (47·1%) were 
women, and the median age was 46 years (IQR 40–53; 
table 1). Demographic and lifestyle characteristics of 
individuals in the GOLD and Aurum datasets were 
similar, except that higher proportions of individuals in 
the Aurum dataset were non-White (399 150 [13·0%] 
of 3 060 297 vs 61 461 [9·6%] of 642 421), residing in 
more deprived regions (627 333 [18·3%] of 3 434 620 vs 
105 045 [13·6%] of 772 985), and current or former 
smokers (2 002 856 [60·1%] of 3 334 866 vs 393 016 [52·6%] 
of 747 925) than in the GOLD dataset (appendix p 5).
526 480 (12·5%) of 4 212 930 individuals had diagnosed 
hypertension: 347 418 at baseline and a further 
179 062 during follow-up. 607 087 (14·4%) individuals 
had a QRISK2 score of 10% or higher: 402 594 at 
baseline, and a further 204 493 had a score that increased 
to 10% or higher during follow-up. 239 184 (5·7%) 
individuals had both hypertension and a QRISK score 
of 10% or higher. 
586 147 episodes of acute respiratory infection were 
recorded among 442 408 individuals: 107 639 episodes of 
influenza or influenza-like illness and 31 068 episodes of 
pneumonia. The incidence of all-cause acute respiratory 
infection and pneumonia increased with age, with the 
exception of the incidence of acute respiratory infection 
among those with a QRISK2 score of 10% or higher, for 
which there was no age trend, and the incidence of 
influenza or influenza-like illness decreased with age 
(appendix p 18). The incidence of acute respiratory 
infection was higher among individuals with 
hypertension (40·3 infections per 1000 person-years 
[95% CI 40·0–40·7]) and a QRISK2 score of 10% or 
higher (43·8 infections per 1000 person-years [43·4–44·2]) 
than among those without hypertension (29·1 infections 
per 1000 person-years [29·0–29·2]) and a QRISK2 score 
of less than 10% (28·8 infections per 1000 person-years 
[28·7–28·9]; table 2).
In the unadjusted analysis, there was an increased 
incidence of acute respiratory infection among 
individuals with hypertension compared with those 
without hypertension (IRR 1·38 [95% CI 1·36–1·39]) 
and similarly for individuals with a QRISK2 score of 
10% or higher compared with those with a QRISK2 
score of less than 10% (1·52 [1·50–1·53]). After 
adjustment for confounders, the association between 
hypertension and acute respiratory infection was 
substantially reduced (IRR 1·04 [95% CI 1·03–1·05]), 
but the association between a QRISK2 score of 10% or 
higher and acute respiratory infection remained (1·39 
[1·37–1·40]; table 2). The increased incidence of 
pneumonia among individuals with hypertension 
compared with those without hypertension (1·12 
[1·07–1·16]), and among individuals with a QRISK2 
score of 10% or higher compared with those with a 
QRISK2 score of less than 10% (2·32 [2·25–2·40]) was 
more pronounced than for all-cause acute respiratory 
infection (table 2). For influenza and influenza-like 
illness, the incidence rate ratio was lower among 
individuals with hypertension than among those 
without hypertension (0·98 [0·96–1·00]), and lower 
among individuals with a QRISK2 score of 10% or 
higher than among those with a QRISK2 score of less 














Hypertension 77 674 40·3 (40·0–40·7) 1·38 (1·36–1·39) 1·33 (1·32–1·34) 1·04 (1·03–1·05)
No hypertension 508 473 29·1 (29·0–29·2) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 81 662 43·8 (43·4–44·2) 1·52 (1·50–1·53) NA 1·39 (1·37–1·40)
QRISK2 <10% 504 485 28·8 (28·7–28·9) 1 (ref) NA 1 (ref)
Influenza or influenza-like illness
Hypertension 12 050 6·3 (6·1–6·4) 1·14 (1·11–1·16) 1·25 (1·22–1·27) 0·98 (0·96–1·00)
No hypertension 95 589 5·5 (5·4–5·5) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 10 010 5·4 (5·3–5·5) 0·96 (0·94–0·98) NA 0·88 (0·86–0·90)
QRISK2 <10% 97 629 5·6 (5·5–5·6) 1 (ref) NA 1 (ref)
Pneumonia
Hypertension 4479 2·3 (2·2–2·4) 1·59 (1·53–1·65) 1·32 (1·27–1·38) 1·12 (1·07–1·16)
No hypertension 26 589 1·5 (1·5–1·5) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 6476 3·5 (3·4–3·6) 2·60 (2·52–2·69) NA 2·32 (2·25–2·40)
QRISK2 <10% 24 592 1·4 (1·4–1·4) 1 (ref) NA 1 (ref)
Total person-years per 1000 years of follow-up available was 1926·2 for hypertension, 17 467·9 for no hypertension, 
1865·1 for a QRISK2 score of 10% or higher, and 17 529·1 for a QRISK2 score of less than 10%. Likelihood ratio test 
p values for all comparisons were less than 0·0001. IRR=incidence rate ratio. NA=not applicable. *Hypertension models 
were adjusted for age, sex, race or ethnicity, socioeconomic status, body-mass index, alcohol consumption, smoking 
status, and consultation frequency; and QRISK2 models were adjusted for alcohol consumption and consultation 
frequency.
Table 2: Association between cardiovascular risk and acute respiratory infection
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The sensitivity analyses, in which we analysed CPRD 
GOLD and Aurum datasets separately (appendix p 6), 
redefined the study population (appendix p 7), and 
compared recorded and calculated QRISK2 scores 
(appendix p 8), showed similar results to those of the 
primary analysis.
Among the 442 408 individuals (with 526 800 acute 
respiratory infection episodes) who had an acute 
respiratory infection, 4169 (0·9%) had an acute 
cardiovascular event within 1 year. 1606 (38·5%) of these 
individuals had pneumonia (appendix p 10).
985 (11·2 events per 1000 person-years [95% CI 
10·5–12·0]) acute cardiovascular events occurred in 
individuals with hypertension, 3184 (5·8 events 
per 1000 person-years [5·6–6·0]) in those without 
hypertension, 1526 (17·5 events per 1000 person-years 
[16·7–18·5]) in individuals with a QRISK2 score of 
10% or higher, and 2643 (4·8 events per 1000 person-
years [4·6–5·0]) in those with a QRISK2 score of less 
than 10% (table 3). The number of acute cardiovascular 
events that occurred in individuals after influenza or 
influenza-like illness and pneumonia, according to 
cardiovascular risk, is shown in the appendix (pp 9–10).
2106 (50·5%) of the 4169 acute cardiovascular events 
occurred within 30 days of an acute respiratory infection 
(appendix p 19), but the median time interval was slightly 
longer in individuals with hypertension (median 41 days 
[IQR 1–168]) or a QRISK2 score of 10% or higher (31 days 
[1–60]) compared with those without hypertension 
(24 days [1–156]) or a QRISK2 score of less than 10% 
(26 days [1–159]). The time interval between pneumonia 
and an acute cardiovascular event was shorter than for 
all-cause acute respiratory infection, whereas the time 
interval for influenza or influenza-like illness was longer 
(appendix p 19). 
After adjustment for confounders, hypertension 
(hazard ratio [HR] 1·98 [95% CI 1·83–2·15]) and a 
QRISK2 score of 10% or higher (3·65 [3·42–3·89]) 
remained associated with acute cardiovascular events 
after acute respiratory infection (table 3). When acute 
cardiovascular events were analysed separately, the HRs 
were largest for acute limb ischaemia, even though there 
were only a small number of events (hypertension vs no 
hypertension HR 4·63 [95% CI 2·68–7·99]; QRISK2 
score of ≥10% vs <10% 6·93 [4·43–10·83]), acute coronary 
syndrome (2·13 [1·86–2·44]; and 4·37 [3·93–4·86]), 
and cardiovascular death (2·15 [1·69–2·73]; and 4·81 
[3·99–5·81]).
In the analysis stratified by prescription of 
antihypertensive, statin, or antiplatelet drugs, there was 
no association between hypertension status and acute 
cardiovascular events after acute respiratory infection 
among individuals with a prescription (antihypertensives 
HR 1·00 [95% CI 0·84–1·18], statins 1·09 [0·91–1·30], 
antiplatelets 0·86 [0·65–1·13]), but the association 
remained for those without a prescription (no anti-
hypertensives 2·62 [2·37–2·89], no statins 2·14 
[1·98–2·32], no antiplatelets 2·05 [1·91–2·21]). A 
QRISK2 score of 10% or higher remained associated 
with acute cardiovascular events after acute respiratory 
infection in patients with and without a prescription of 
antihyper tensives, statins, or antiplatelets, but was 
higher among individuals without a prescription (anti-
hyper tensives 2·45 [2·11–2·85] vs no antihypertensives 
4·04 [3·76–4·34], statins 2·22 [1·83–2·69] vs no statins 
3·93 [3·67–4·21], antiplatelets 1·82 [1·36–2·44] vs no 
antiplatelets 3·68 [3·45–3·93]; figure 2; appendix p 11). 














Hypertension 985 11·2 (10·5–12·0) 2·08 (1·93–2·23) 1·97 (1·84–2·12) 1·98 (1·83–2·15)
No hypertension 3184 5·8 (5·6–6·0) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 1526 17·5 (16·7–18·5) 3·74 (3·51–3·98) NA 3·65 (3·42–3·89)
QRISK2 <10% 2643 4·8 (4·6–5·0) 1 (ref) NA 1 (ref)
Acute coronary syndrome†
Hypertension 372 4·2 (3·8–4·7) 2·19 (1·95–2·46) 2·06 (1·83–2·32) 2·13 (1·86–2·44)
No hypertension 1140 2·1 (1·9–2·2) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 613 7·0 (6·5–7·6) 4·42 (3·98–4·89) NA 4·37 (3·93–4·86)
QRISK2 <10% 899 1·6 (1·5–1·7) 1 (ref) NA 1 (ref)
Heart failure
Hypertension 290 3·3 (2·9–3·7) 2·04 (1·79–2·32) 1·92 (1·69–2·19) 2·08 (1·79–2·42)
No hypertension 961 1·7 (1·6–1·9) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 478 5·5 (5·0–6·0) 4·00 (3·57–4·49) NA 3·85 (3·42–4·34)
QRISK2 <10% 773 1·4 (1·3–1·5) 1 (ref) NA 1 (ref)
Acute limb ischaemia
Hypertension 25 0·3 (0·2–0·4) 2·98 (1·85–4·78) 2·82 (1·74–4·55) 4·63 (2·68–7·99)
No hypertension 55 0·1 (0·1–0·1) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 42 0·5 (0·4–0·7) 7·55 (4·62–11·07) NA 6·93 (4·43–10·83)
QRISK2 <10% 38 0·1 (0·1–0·1) 1 (ref) NA 1 (ref)
Stroke or transient ischaemic attack‡
Hypertension 360 4·1 (3·7–4·6) 2·15 (1·91–2·42) 2·08 (1·84–2·34) 2·01 (1·75–2·29)
No hypertension 1120 2·0 (1·9–2·1) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 468 5·4 (4·9–5·9) 2·99 (2·68–3·34) NA 2·93 (2·62–3·28)
QRISK2 <10% 1012 1·8 (1·7–1·9) 1 (ref) NA 1 (ref)
Cardiovascular-related death
Hypertension 129 1·5 (1·2–1·8) 2·11 (1·73–2·58) 1·99 (1·63–2·43) 2·15 (1·69–2·73)
No hypertension 413 0·7 (0·7–0·8) 1 (ref) 1 (ref) 1 (ref)
QRISK2 ≥10% 230 2·6 (2·3–3·0) 4·77 (4·03–5·66) NA 4·81 (3·99–5·81)
QRISK2 <10% 312 0·6 (0·5–0·6) 1 (ref) NA 1 (ref)
Total person-years per 1000 years of follow-up available was 87·9 for hypertension, 553·6 for no hypertension, 87·0 
for a QRISK2 score of 10% or higher, and 554·4 for a QRISK2 score of less than 10%. Likelihood ratio test p values for all 
comparisons were less than 0·0001. HR=hazard ratio. NA=not applicable. *Hypertension models were adjusted for age, 
sex, race or ethnicity, socioeconomic status, body-mass index, alcohol consumption, and smoking status; QRISK2 
models were adjusted for alcohol consumption. †Fully adjusted HR for myocardial infarction alone was 2·22 (95% CI 
1·91–2·59) in the hypertension model and 4·89 (4·35–5·51) in the QRISK2 model; fully adjusted HR for angina alone 
was 2·03 (1·51–2·72) in the hypertension model and 3·06 (2·38–3·93) in the QRISK2 model. ‡Fully adjusted HR for 
stroke was 2·10 (95% CI 1·81–2·43) in the hypertension model and 2·90 (2·56–3·30) in the QRISK2 model; and fully 
adjusted HR for transient ischaemic stroke alone was 1·77 (1·34–2·33) in the hypertension model and 3·10 (2·46–3·90) 
in the QRISK2 model. 
Table 3: Incidence and risk of acute cardiovascular events after acute respiratory infection by 
cardiovascular risk group 
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prescription of antihypertensive, statin and antiplatelet 
drugs were significant (likelihood ratio test p<0·0001). 
The sensitivity analyses, in which we analysed the 
CPRD GOLD and Aurum datasets separately (appendix 
pp 12–13), redefined the study population (appendix p 14), 
compared recorded and calculated QRISK2 scores 
(appendix p 15), redefined the outcome to include only 
major adverse cardiovascular events (appendix p 16), 
and excluded individuals who received influenza or 
pneumococcal vaccines during the follow-up period 
(appendix p 17), showed similar results to those of the 
primary analysis.
Discussion 
In our study population of more than 4·2 million adults 
aged 40–64 years who did not have chronic health 
conditions and were ineligible for influenza vaccination, 
the incidence of both acute respiratory infection and 
acute cardiovascular events after acute respiratory 
infection was increased in individuals with elevated 
cardiovascular risk, measured by diagnosed hyper tension 
or a QRISK2 score of 10% or higher. The incidence of 
acute respiratory infection was 1·4–1·5 times higher 
among individuals with increased cardiovascular risk 
than in those without. After adjustment for confounders, 
this increase in incidence was marginal when risk 
was defined by diagnosed hypertension and more 
substantial when defined by QRISK2 scores. We observed 
a substantially larger increase in risk of an acute 
cardiovascular event after respiratory infection when 
individuals were stratified by QRISK2 score (3·7 times) 
than by diagnosed hyper tension (2·0 times). Associations 
were similar for all-cause acute respiratory infection, 
influenza-like illness, and pneumonia. Half of the acute 
cardiovascular events occurred within 30 days of acute 
respiratory infection.
Our finding that the incidence of acute respiratory 
infection was elevated among individuals with increased 
cardiovascular risk is consistent with the results of a 
recent UK Biobank study, which examined the association 
between blood pressure and the risk of different 
respiratory infections.14 Participants with prevalent 
Figure 2: Risk of an acute cardiovascular event after an acute respiratory infection in the hypertension model (A) and in the QRISK2 score model (B) by 
stratifying factor 
HRs were adjusted for age, sex, race or ethnicity, socioeconomic status, body-mass index, alcohol intake, and smoking status in the hypertension model, and for 
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hypertension had an increased risk of pneumonia 
(HR 1·36 [95% CI 1·29–1·43]), influenza or viral 
pneumonia (1·12 [1·01–1·23]), and other lower 
respiratory infections (1·15 [1·11–1·19]). In our study, the 
increased incidence of acute respiratory infection among 
individuals with hypertension, measured by recorded 
diagnoses, was smaller than observed in the UK Biobank 
study. Instead, we found more substantial increases 
in the incidence of acute respiratory infection in 
individuals with a QRISK2 score of 10% or higher, which 
includes systolic blood pressure reading and use of 
antihypertensive drugs. Only 39% (239 194 of 607 087) of 
individuals with a QRISK2 score of 10% or higher had 
diagnosed hypertension. Other UK cohort studies have 
reported increases in the incidence of influenza-like 
illness to be associated with non-White ethnicity and 
social deprivation,22,23 both of which are cardiovascular 
risk factors included in the QRISK2 algorithm and can 
result in higher QRISK2 scores assigned to individuals 
with these characteristics.
Previous studies have reported transient increases in 
the risk of myocardial infarction and stroke after acute 
respiratory infection.1–4 In the few published observational 
studies that consider the effect of cardiovascular risk 
on this association, the results were mixed. In two 
studies, hypertension was associated with an increase in 
cardiovascular complications after pneumonia.15,16 In 
another study, there was no difference in the likelihood 
of first myocardial infarction or stroke occurring after 
acute respiratory infection when stratified by the 
presence of cardiovascular risk factors.17 Studies done 
during the COVID-19 pandemic have generally shown a 
high prevalence of cardiovascular disease risk factors in 
people hospitalised or those who died due to COVID-19. 
Pooled results suggest that the risk of severe COVID-19 
outcomes is 2–3 times higher among hospitalised 
individuals with hypertension or diabetes than those 
without hypertension or diabetes.24 The degree to which 
age drives these associations, especially for hypertension, 
is unclear, with age-adjusted analyses showing varying 
results.24
Several mechanisms could explain the associations 
between cardiovascular risk factors, acute respiratory 
infection, and cardiovascular disease. Hypertension could 
promote immune dysregulation, leading to infection, or 
the endothelial dysfunction caused by hypertension, 
hyperlipidaemia, and diabetes could promote infection.25,26 
Infectious agents, such as SARS-CoV-2, the influenza 
virus, and S pneumoniae, could also exacerbate 
atherosclerotic processes. The infectious agent could have 
direct effects on vascular cells, or the infection could 
induce haemodynamic, inflammatory, and procoagulant 
processes. The release of proinflammatory cytokines in 
response to an infection can mediate atherosclerosis or 
directly affect plaque rupture.26 Endothelial dysfunction, 
caused by a range of cardiovascular risk factors, is a key 
early stage of atherosclerosis.26
A strength of our study is that we used large, 
population-based, linked datasets generalisable to the 
UK population. We also compared results across two 
measures of cardiovascular risk. The marked increase in 
the incidence of acute cardiovascular events after acute 
respiratory infection in individuals with a QRISK2 
score of 10% of higher compared with those with 
diagnosed hypertension is consistent with the multiple 
cardiovascular risk factors accounted for in the QRISK2 
score.
Our selected study population should have reduced 
confounding. We included only individuals without 
chronic health conditions, who were not thought to be at 
high risk of acute respiratory infection or complications 
related to acute respiratory infection, and who were not 
recommended for influenza vaccination in England, 
according to current guidance. However, the selective 
study population prevented comparison of the incidence 
of acute respiratory infection and acute cardiovascular 
events after acute respiratory infection among individuals 
with established cardiovascular disease.
In England, diagnoses of acute respiratory infection are 
based primarily on clinical judgement, with most cases 
not laboratory confirmed. We included only codes that 
were most likely to be representative of systemic 
infection, which could plausibly induce atherosclerotic 
processes. However, clinically diagnosed influenza is 
poorly defined.27 An under-estimation of the incidence of 
some acute respiratory infections, particularly influenza-
like illness, is likely to occur because it is a short-lived 
illness. Conversely, due to its severity, pneumonia 
will usually result in health-care attendance. These 
differences in presentation and EHR data capture could 
account for the differing incidence of influenza-like 
illness and pneumonia among individuals with increased 
cardiovascular risk. From 1995 to 2013, recording of 
influenza-like illness decreased while recording of cough 
or fever symptoms increased in UK primary care,27 and 
recording of community-acquired pneumonia increased 
in primary and secondary care.28 Recording of symptoms, 
rather than diagnosis, in individuals with a QRISK2 
score of 10% or higher, who were likely to attend primary 
care for comorbid conditions, could account for the lower 
incidence of influenza-like illness in these individuals 
than in those who had a QRISK2 score of less than 10%.
We might have misclassified QRISK2 score due to 
missing data for variables used in its calculation. 
However, the similar results from primary care recorded 
and captured in CPRD and our calculated QRISK2 
scores suggest minimal misclassification. Furthermore, 
we adjusted for consultation frequency, as individuals 
who infrequently attend primary care services are 
unlikely to have biometric measures such as BMI or 
blood pressure recorded. We used a pragmatic definition 
for hypertension based on coded diagnoses only; 
this coded diagnosis corresponds to how, if eligible, 
individuals would be identified for influenza and 
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pneumococcal vaccination in primary care. We are likely 
to have captured both controlled and uncontrolled 
hypertension. In the stratified analysis, 38% (25 843 of 
68 731) of individuals with diagnosed hypertension had 
not been prescribed antihypertensive drugs in the year 
before the acute respiratory infection. Conversely, only 
3% (14 912 of 458 069) of individuals without a diagnosis 
of hypertension were prescribed antihypertensive 
drugs. Possible misclassification could have biased the 
results towards the null, which could explain the 
small association observed between hypertension and 
acute respiratory infection compared with the larger 
association for QRISK2 scores in our study and blood 
pressure reading-defined hypertension in the UK 
Biobank study.14
We assumed that acute cardiovascular events occurring 
after acute respiratory infection were due to infection. 
However, some events could have been unrelated, 
particularly those that occurred several months after 
infection. The possibility of unrelated events is consistent 
with our finding of a longer median time between acute 
respiratory infection and acute cardiovascular events in 
individuals with increased cardiovascular risk compared 
with those without an increased risk, as those with an 
increased cardiovascular risk are more likely to have a 
cardiovascular event regardless of acute respiratory 
infection.
Our findings emphasise the importance of improved 
cardiovascular risk management, which could reduce 
the incidence of acute respiratory infection and its 
cardiovascular consequences. The COVID-19 pandemic 
has highlighted this need. Preventive cardiovascular 
treatments, particularly among individuals with a QRISK2 
score of 10% or higher, could reduce acute respiratory 
infection-related complications. A meta-analysis of nine 
observational studies showed a 41% reduction in the odds 
of mortality within 30 days of having pneumonia among 
statin users.29 Targeted interventions for individuals with 
acute respiratory infection and a QRISK2 score of 10% 
or higher should be considered. A CPRD-based study 
published in 2020 found that aspirin use after hospitali-
sation for pneumonia resulted in a 54% reduction in the 
incidence of myocardial infarction and a 30% reduction in 
the incidence of stroke.30
Typically, individuals with increased cardiovascular risk 
do not receive seasonal influenza or pneumococcal 
vaccines. Previous RCTs have shown that the influenza 
vaccine provides secondary prevention of cardiovascular 
disease.7 However, no RCTs or observational studies have 
investigated the use of vaccines for primary prevention of 
cardiovascular complications. Extending influenza 
vaccination to individuals with a QRISK2 score of 10% or 
higher would, on the basis of the most recent year in our 
data set (2017–18), include approximately 150 000 indi-
viduals in England. Vaccinating these indiv iduals could 
reduce cardiovascular complications and presumably 
decrease the incidence of influenza and associated 
complications, such as hospitalisation and mortality. 
Future studies using laboratory data to ascertain whether 
specific organisms lead to increases in cardiovascular 
events in people with increased cardiovascular risk would 
inform potential expansion of vaccine prioritisation.
In conclusion, the results of our study suggest that the 
incidence of acute respiratory infection, particularly 
pneumonia, is increased in people with high 
cardiovascular risk, and that the incidence of acute 
cardiovascular events after acute respiratory infection is 
also increased in these individuals. The QRISK2 score 
provides a better measure of the risk of a first 
cardiovascular event following acute respiratory infection 
than a diagnosis of hypertension alone. Therefore, the 
QRISK2 score could be used not only to identify 
individuals who require cardiovascular risk management, 
but also to target prevention and treatment of acute 
respiratory infection to individuals at increased risk of 
cardiovascular events following infection.
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